PF-06835919 is primarily investigated for its potential therapeutic applications in the treatment of metabolic disorders, particularly type 2 diabetes. It functions as a ketohexokinase (KHK) inhibitor, targeting the metabolism of fructose. By inhibiting KHK, it reduces the conversion of fructose to fructose-1-phosphate, thereby lowering the accumulation of harmful metabolites that contribute to insulin resistance, fatty liver disease, and other metabolic complications. This mechanism makes it a promising candidate for managing conditions linked to excessive fructose consumption. Clinical trials are ongoing to evaluate its efficacy and safety in improving glycemic control and reducing liver fat in patients with metabolic syndrome or related disorders. Its development highlights a novel approach to addressing the underlying metabolic dysfunctions associated with modern dietary habits.